NCT03382990

Stent Placement and the Risk of New-onset AF in Patients With AMI

The Impacts of Different Stent Types in Acute Myocardial Infarction on the Risk of Atrial Fibrillation

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 40,000 (estimated)
• Sponsor: Mackay Memorial Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The benefit of a drug-eluting stent (DES) in patients with acute myocardial infarction (AMI) is controversial. This study will aim to observe the effect of a DES on the risk of new-onset AF in patients with AMI.

Detailed description

Acute myocardial infarction (AMI) is the leading cause of mortality in the world. Early invasive strategy with percutaneous coronary intervention (PCI) has been demonstrated to be the most effective strategy to treat AMI. Although drug-eluting stent (DES) has not shown benefits to reduce mortality rate among AMI patients compared with bare-metal stent (BMS), the use of DES in real-world is increasing because of reduced restenosis rates. AMI patients are at higher risk to develop atrial fibrillation (AF) than general population. However, whether early PCI with DES implantation is related to a reduced risk of AF still remains unclear. The purpose of this study is to investigate the association of DES implantation and the risk of AF among patients with AMI treated by early PCI.

Conditions

• Atrial Fibrillation New Onset
• Acute Myocardial Infarction

Interventions

Type	Name	Description
DEVICE	DES or BMS	DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.

Timeline

• Start date: 2018-01-01
• Primary completion: 2018-12-31
• Completion: 2019-12-31
• First posted: 2017-12-26
• Last updated: 2017-12-26

Regulatory

• FDA-regulated device study